Bayer and the Massachusetts Biotechnology Council (MassBio) are this week opening a regulatory best practice center for startup biotech and digital health companies. Their goal? Get new drug developers to start thinking about regulatory requirements earlier.
“Getting some kind of regulatory insights much earlier in the decision-making process can help startups in terms of formulating a path to get to the patient market more quickly. We thought that we should do this right now, especially as the entire regulatory landscape is changing,” Chandra Ramanathan, Bayer global head of R&D open innovation, said.